Astellas dumps Theravance's MRSA drug Vibativ

Astellas Pharma parted ways with Theravance ($THRX), ending a promotional partnership on the infection-fighter Vibativ. FDA-approved in 2009, the drug targets infections caused by resistant staph bacteria. Theravance said it is looking for a new marketing partner and working on "re-establishing" consistent supplies of the product. Report

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.